Sydney-based biopharmaceutical firm, Kazia Therapeutics Limited, has been making strides in the development of anti-cancer drugs. Its leading development candidate, Paxalisib, is a brain-penetrant inhibitor of the PI3K/Akt/mTor pathway which offers promising potential as a therapy for glioblastoma. In addition, the company is currently in the developmental stages of EVT801, an investigational drug that could potentially treat multiple forms of cancer. Prior to November 2017, Kazia Therapeutics was known as Novogen Limited. Established in 1994, the company has since focused its efforts on the development of oncology-related treatments.